Abstract: Administration regimens for therapeutic proteins (e.g., T cell-activating bispecific antibodies) that mitigate cytokine release syndrome and infusion-related reaction are disclosed. The methods employ initial fractional dosing with optional administration of additional agents such as steroids or cytokine antagonists that are discontinued with maximal weekly dosing over the course of the dosing regimen.

Abstract: This invention relates to antibody therapies for human immunodeficiency virus (HIV). In particular, the invention provides methods of curing subjects infected with HIV and blocking HIV infections in subjects at risk of HIV transmission using a N332 glycan-dependent antibody (e.g., PGT121).

Abstract: Provided are methods of producing cobalt-based nanoparticles (CoxBy NPs) of a pre-selected diameter. The methods include reducing Co2+ ions with a sodium borohydride (NaBH4) solution having a selected ratio of tetrahydroxyborate (B(OH)4?) to tetrahydroborate (BH4?) based on the pre-selected diameter, where the ratio of B(OH)4? to BH4? is positively correlated with the pre-selected diameter. Also provided are methods of using the CoxBy NPs to produce hollow metal nanospheres (HMNs). Methods of producing CoxBy NP core/metal shell structures are also provided, such methods including combining in an anaerobic galvanic exchange reaction a deaerated solution including CoxBy NP scaffolds and a deaerated solution including a metal. Also provided are methods of producing HMNs from the CoxBy NP core/metal shell structures. Compositions and kits that find use in practicing the methods of the present disclosure and using HMNs produced in accordance with the methods of the present disclosure, are also provided.

Abstract: This current disclosure is directed to compositions based on certain heptamethine dyes useful for generating singlet oxygen using NIR radiation, optionally comprising additives and solvents that enhance the performance of these dyes, and procedures using these compositions to modify treat myopia and other ocular conditions. In some cases, the methods use near-infrared irradiation to improve the mechanical strength of the sclera.

Abstract: Disclosed are compositions and methods for screening drugs that treat neurodegenerative disorders and methods of treating neurodegenerative orders with combinations of said drugs.

Abstract: Methods of forming antimicrobial biopolymers from sodium alginate and algae extract using aminoglycosides are presented. Also presented are improved biopolymers, methods of making the biopolymers, and methods of using the biopolymers, wherein the biopolymer includes a sodium alginate and an aminoglycoside.

Abstract: Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating COPD and/or PF.

Abstract: Compositions and method are therefore disclosed for treating asthma. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating asthma.

Abstract: Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

Abstract: Disclosed is an anticancer prodrug that disturbs energy metabolism in cancer cells to overcome drug resistance. The anticancer prodrug has a structure including a pyruvate dehydrogenase kinase (PDK) inhibitor moiety, a mitochondrial targeting group, and an anthracycline moiety reversibly connected to the PDK inhibitor moiety and the targeting group.

Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

Abstract: Zwitterionic monomers, carnitine-derived zwitterionic polymers, carnitine ester cationic monomers, carnitine ester cationic polymers, conjugate compositions including a carnitine-derived zwitterionic polymer, and related compositions' and methods are provided which have various uses including as coatings, pharmaceuticals, diagnostics, encapsulation materials, and antifouling materials, among other utilities.

Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

Abstract: The present invention relates to a method of treating cancer in a subject.

Abstract: Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Abstract: A stable c-Met antibody-drug conjugate (c-Met ADC) formulation and use thereof in medicine are described. In particular, the formulation contains c-Met ADC, a buffer, and can also contains at least one stabilizer, and optionally a surfactant. The c-Met ADC formulation of the application can effectively inhibit the aggregation and isomerization of antibodies, and prevent the degradation of an antibody product therein, being a stable injectable pharmaceutical formulation.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs), and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptide variants that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPs change selectivity from broad spectrum antimicrobial activity to Gram-negative selectivity.

Abstract: By inserting cysteine (C) into a heavy chain and/or a light chain of a target antibody at specific insertion site, and performing a site-specific conjugation through a free thiol group (—SH) from the site-specific inserted cysteine and a linker conjugated with a highly potent small molecule cytotoxin, a cysteine modified antibody-drug conjugate with good homogeneity is provided.

Abstract: The invention provides methods for selective targeting of live cells, which have undergone or are undergoing radiation or chemotherapy, at a site of interest with a cell-penetrating polypeptide. In one embodiment of the invention, the method comprises contacting the live cells with a cell-penetrating polypeptide comprising cell-penetrating determinants so that the cell-penetrating polypeptide binds extracellular DNA near or around the live cells so as to form a complex or association therewith such that the complex or associated polypeptide-DNA so bound bind the live cells and penetrates the live cells thereby selectively targeting live cells at a site of interest with a cell-penetrating polypeptide.

Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Abstract: The present disclosure provides, inter alia, multi-drug Antibody Drug Conjugates (MD-ADCs) and Linking Assembly (LA) Units, that are constructed in a site-specific matter via ‘orthogonal’ deprotection and drug loading. Also provided are, Protected Linking Assembly Units, which allow for ‘orthogonal’ deprotection and construction of MD-ADCs and LA Units of the present disclosure.

Abstract: The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

Abstract: A synthetic gene delivery platform with a dense surface coating of hydrophilic and neutrally charged PEG, capable of rapid diffusion and widespread distribution in brain tissue, and highly effective gene delivery to target cells therein has been developed. Nanoparticles including nucleic acids, are formed of a blend of biocompatible hydrophilic cationic polymers and they hydrophilic cationic polymer conjugated to hydrophilic neutrally charged polymers such as polyethylene glycol. The nanoparticles are coated with polyethylene glycol at a density that imparts a near neutral charge and optimizes rapid diffusion through the brain parenchyma. Methods of treating a disease or disorder of the brain including administering a therapeutically effective amount of nanoparticles densely coated with polyethylene glycol are also provided.

Abstract: The present invention relates to a resorbable implant material made of magnesium or magnesium alloy and to a process for the production thereof. A disadvantage of the known resorbable implants is that their resorption has hitherto only been trackable using x-ray or CT examinations. The invention provides a resorbable implant material comprising homogeneously distributed fluorescent nanodiamonds in a matrix of magnesium or a magnesium alloy. Fluorescent nanodiamonds are biologically nonhazardous and provide a stable emission in the near infrared range due to nitrogen-vacancy centers (NV centres). This allows detection of the implant material in the blood plasma of the patient. The resorbable implant material according to the invention is produced by a process wherein magnesium or a magnesium alloy is melted, nanodiamonds are added to the melt and the melt of magnesium or a magnesium alloy provided with nanodiamonds is subjected to an ultrasound treatment.

Abstract: Herein described are solid oral compositions of dyes for use in diagnostic endoscopy, preferably colon endoscopy.

Abstract: The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

Abstract: The present invention provides contrast agents of the formula [N(A1,A2,A3) M](counter ion(s)) for use in a diagnostic method practiced on the human or animal body. It also refers to the contrast agents, as well as pharmaceutical compositions containing same. Further, it relates to a method of in vitro medical imaging, especially of diagnostic imaging, comprising administering said compound to a sample.

Abstract: A radioactive labeled long-acting peptide-targeting pharmaceutical and production method, in which the peptide targeted pharmaceutical is firstly dissolved in a solution, followed by labeling the radioactive at a high temperature, and the dosage of the pharmaceutical with radioactive labeling is expected to be reduced and labeling efficiency is improved, and no further purification by filtration is required, which shortens the preparation process and reduces personnel exposure in the working environment. The radioactive labeled long-acting peptide-targeting pharmaceutical can increase the specific binding capacity of tumors and reduce the non-specific accumulation in normal tissues. It can be applied to the field of tumor and nuclear medicine for diagnosis and treatment of tumors and/or tumor metastases with efficacy and precision treatment.

Abstract: Methods for determining systemic biodistribution characteristics of intravitrially administered medicaments. In some embodiments, radiolabeled agents or medicaments, such as I-124 labeled bevacizumab, ranibizumab and aflibercept, was imaged utilizing PET/CT in a non-human primate model, with radioactivity emission measurements made to determine the intravitreal half-lives of each agent and to determine the differences of radioactivity uptake in non-ocular organs.

Abstract: The present invention relates to a sponge dressing for treating wounds comprised of a polymer sponge containing a plurality of antimicrobial dyes with at least one dye being gram positive and at least one other dye being gram negative and a silicon adhesive secured to a sponge surface. The sponge dressing can be exposed initially to gamma radiation and later sterilized by ethylene oxide or alternatively it can be sterilized by ethylene oxide and later irradiated by gamma radiation. The sponge dressing has a morphology characterized by an average pore throat diameter of 0.5-500 ?m and a porosity ranging from about 60% to about 99.5%. The sponge dressing can also contain at least one biofilm reducing agent, at least one chelating agent and an ionic and non-ionic surfactant.

Abstract: The present invention deals with a new unimodal propylene-ethylene random copolymer providing improved resistance against gamma irradiation as well as compositions comprising the new unimodal propylene-ethylene random copolymer and final articles made therefrom.

Abstract: A mask storage apparatus includes a body including an accommodation space in which a mask device is stored. A cover is rotatably connected to the body and is capable of opening and closing the accommodation space. A compartment extends from an inner surface of the body and partitions the accommodation space into a first accommodation space in which a part of the mask device is accommodated, and a second accommodation space in which a remaining part of the mask device is accommodated. The compartment includes a sterilization module to sterilize the mask device.

Abstract: A sterilization system includes a sterilization chamber, a processor, and a sterilization module. The sterilization module includes a frame assembly, an extraction assembly, and a carriage assembly. The extraction assembly is configured to extract a sterilant fluid from a cartridge and transfer the sterilant fluid to the sterilization chamber. The carriage assembly includes a motor, a carriage body, and a translating flag. The carriage body is configured to receive the cartridge. The translating flag is configured to move from a first position to a second position relative to the carriage body in response to the carriage body receiving the cartridge. The sensor is configured to detect movement of the translating flag from the first position to the second position.

Abstract: Disclosed herein are apparatuses and methods for generating non-thermal plasma which can form reactive oxygen species (ROS), such as those used to neutralize bacteria and other pathogens in the air and surrounding area. Also disclosed are apparatuses and methods for neutralizing bacteria and other pathogens using ROS generated through the use of non-thermal plasma. Also disclosed are apparatuses and methods for generating ROS. Also disclosed are apparatuses and methods for treating air and nearby surfaces. Also disclosed herein are apparatuses for generating non-thermal plasma, and which can monitor and analyze the operational characteristics of a plasma field generated by the aforementioned devices and/or the electrical consumption characteristics of the power supply being used to generate the plasma field, which analyzed characteristics can be used to trigger an alarm to indicate that the device is not functioning optimally or as otherwise expected.

Abstract: An instrument cassette (100) for handling instruments (111) comprises support structures (101) for mechanically supporting the instruments (111), and a shielding structure (102, 103) for containing operational portions (112) of the instruments (111) so that a risk of unintentional touching the operational portions (112) is reduced. At least one wall (104) of the shielding structure (103) comprises channels (105) for allowing liquid and gaseous substances to flow through the wall. The substances may comprise for example hot vapor used in an autoclaving sterilization process. The channels (105) are shaped to prevent the operational portions (112) of the instruments (111) from protruding through the wall (104) via the channels (105). Thus, there is no need for a high number of very small channels which may be difficult to manufacture in a cost effective way.

Abstract: The present invention relates to a dressing providing for the controlled and sustained release of metformin. The present invention relates in particular to the use of a resin selected from the aromatic resins, to promote the release of metformin into an elastomeric matrix.

Abstract: The present invention relates to a hydrophilic foam material, which is of particular use in wound treatment, and to a method for producing said hydrophilic foam material. The hydrophilic foam material has nucleating particles, wherein at least 85% of all foam cells in said foam material have an average cell size of 0.01 mm2 or less.

Abstract: The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.

Abstract: An objective of the present invention is to provide an absorbent article that prevents wetting of the outer sides or surrounding area of the absorbent article due to condensation formed by water vapor escaped from inside the absorbent article. The present invention provides an absorbent article comprising: an absorbent body composed of at least one absorption layer, wherein the absorbent body includes a hydrophobized adsorbent and (a) a water absorbent resin powder having an absorption speed in a range from 6 seconds to 60 seconds determined by a vortex method.

Abstract: Absorbent articles having components bearing graphics printed using particular inkjet ink compositions and fluid sets are disclosed. The aqueous inkjet ink compositions may include a composition consisting of one or more compounds represented by the following Structure I: HO—CH2—CH2—R ??(I) wherein R may be a substituted or unsubstituted phenyl group or a substituted or unsubstituted phenoxy group. Printed regions of components of the articles may bear deposits of dried ink including constituents of the disclosed compositions, that include the one or more Structure I compound(s). The presence of the Structure I compounds in the printed regions may have an effect of inhibiting bacterial growth thereon.

Abstract: An implantable article comprising a dissolvable sponge derived from the mixture of chitosan, a first polysaccharide and a second polysaccharides. The polysaccharides have different number average molecular weight characteristics to enable the control of the mechanical features of the sponge.

Abstract: A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer.

Abstract: Embodiments of the invention include nerve-repair conduits incorporating mats, sheets, and/or powders of silica fibers and methods for producing such conduits. The silica fibers may be formed via electrospinning of a sol gel produced with a silicon alkoxide reagent, such as tetraethyl ortho silicate, alcohol solvent, and an acid catalyst.

Abstract: An orthopedic implant having a metal surface and a hydroxyapatite layer comprising gallium ions therein disposed on at least part of the metal surface is described. The hydroxyapatite layer has an average crystallite size of less than about 75 nm in at least one direction and dissolves for more than 2 hours in vitro. The hydroxyapatite layer is substantially free of carbonate. The coating, which is formed on a sodium titanate surface, has increased shear strength and tensile strength. The coating is formed by a solution deposited hydroxyapatite process under inert conditions. The pH of the solution varies by less than 0.1 pH unit/hour during coating formation.

Abstract: The disclosure provides a preparation method of a hollow porous spherical particle artificial bone. The method comprises: (1) uniformly mixing bioceramic powder, bioglass powder and an excipient to obtain a solid-phase mixture, then adding binder solution to the solid-phase mixture, and uniformly mixing to obtain a plastic wet material; (2) loading a plastic wet material into an extrusion device of an extrusion rounder to be extruded by the orifice plate of the extrusion device to form a strip-shaped material; (3) putting the strip-shaped material into the spheronization device, cutting, and then spheronizing to form spherical particles; and (4) placing the spherical particles into a furnace, debinding, removing the excipient and the binder, and then sintering at 750-1550° C.

Abstract: According to the present invention, there are provided a chamber for transplantation, including a membrane for immunoisolation at a boundary between an inside and an outside of the chamber for transplantation, in which the membrane for immunoisolation includes a porous membrane, and in the porous membrane, a maximum heat shrinkage ratio among heat shrinkage ratios in a membrane surface direction after immersion in water at 90° C. for 3 hours is 0.00% to 5.00%, and a difference between the maximum heat shrinkage ratio and a minimum heat shrinkage ratio among the heat shrinkage ratios in the membrane surface direction is 0.00% to 1.30%; and a device for transplantation including the chamber for transplantation enclosing a biological constituent therein. The chamber for transplantation of the present invention has a high durability and is capable of maintaining an enclosed biological constituent for a long period of time.

Abstract: Nanofiber-based biomaterials containing fibroin for wound repair and tissue replacement are provided with methods of making and using the same.

Abstract: Disclosed are tissue graft compositions made of materials having different densities, methods of making, and methods of treatment for restoring t issues in a patient.